TAN Hualiang,XU Yin,XIAO Lin,et al.Clinical Study on Qilian Jiechangning Decoction for Treatment of Diarrhea-predominant Irritable Bowel Syndrome with Spleen Deficiency and Damp Heat Syndrome[J].zhongguo zhongyiyao xinxi zazhi,2021,28(2):92-96.[doi:10.19879/j.cnki.1005-5304.202008007]
芪连结肠宁方治疗腹泻型肠易激综合征脾虚湿热证临床研究
- Title:
- Clinical Study on Qilian Jiechangning Decoction for Treatment of Diarrhea-predominant Irritable Bowel Syndrome with Spleen Deficiency and Damp Heat Syndrome
- 文章编号:
- 1005-5304(2021)02-0092-05
- Keywords:
- diarrhea-predominant irritable bowel syndrome; spleen deficiency and damp heat syndrome; Qilian Jiechangning Decoction; brain gut peptide; intestinal mucosal barrier function
- 分类号:
- R259.746.2
- 文献标志码:
- A
- 摘要:
- 目的 观察芪连结肠宁方治疗腹泻型肠易激综合征（IBS-D）脾虚湿热证的临床疗效、安全性，以及对脑肠肽、肠黏膜屏障功能的影响。方法 采用随机数字表法将96例患者分为观察组和对照组各48例，治疗期间观察组脱落3例，对照组脱落2例、失访1例。观察组予芪连结肠宁方，每日1剂，每日2次，口服。对照组予马来酸曲美布汀胶囊，0.2 g/次，3次/d，口服；双歧杆菌四联活菌片，0.5 g/次，3次/d，口服。2组均连续治疗4周。观察2组临床疗效，比较2组治疗前后中医症状评分、肠易激综合征症状严重程度量表（IBS-SSS）积分、肠易激综合征生活质量量表（IBS-QOL）评分及血清5-羟色胺（5-HT）、血管活性肠肽（VIP）、P物质、二胺氧化酶（DAO）、D-乳酸、内毒素（ET）水平，并进行安全性评价。结果 观察组总有效率为91.11%（41/45），对照组为82.22%（37/45），2组比较差异有统计学意义（P＜0.05）。与本组治疗前比较，2组治疗后腹痛、大便稀溏、神疲倦怠、大便频次、纳呆评分及IBS-BSS积分降低，IBS-QOL积分升高（P＜0.05）；2组治疗后比较，观察组腹痛、大便稀溏、神疲倦怠、大便频次、纳呆评分明显低于对照组（P＜0.05），IBS-BSS评分低于对照组（P＜0.01），IBS-QOL评分高于对照组（P＜0.01）。与本组治疗前比较，2组治疗后5-HT、VIP、P物质、DAO、D-乳酸及ET水平降低（P＜0.05）；2组治疗后比较，观察组5-HT、VIP、P物质、DAO、D-乳酸及ET水平低于对照组（P＜0.01）。2组均未见不良反应。结论 芪连结肠宁方治疗IBS-D脾虚湿热证疗效较好，可改善患者中医症状评分，提高生活质量，调节脑肠肽水平，改善肠黏膜屏障功能，安全性较好。
- Abstract:
- Objective To observe the clinical efficacy and safety of Qilian Jiechangning Decoction for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) with spleen deficiency and damp heat syndrome and its effects on brain-gut peptide and intestinal mucosal barrier function. Methods Totally 96 patients were divided into the observation group and the control group (48 cases in each group) by random number table method. 45 patients in observation group completed the therapy (3 patients were falling off), and 45 patients in control group completed the therapy (2 patients were falling off and 1 patient was missing). The observation group was given Qilian Jiechangning Decoction, 1 dosage a day, twice a day, orally. T he control group was given trimebutine maleate capsules, 0.2 g per time, three time a day, orally; and Bifidobacterium quadruple viable tablets , 0.5 g per time, three time a day, orally. The course of treatment in both groups was 4 weeks. The clinical efficacy of the two groups was observed. TCM symptom scores, IBS-SSS score, IBS-QOL score, serum 5-HT, VIP, SP, DAO, D-lactic acid, endotoxin (ET) , levels were compared between the two groups before and after treatment. Clinical safety was evaluated. Results The total effective rate of the observation group was 91.11% (41/45) and that of the control group was 82.22% (37/45), with statistical significance (P<0.05). Compared with before treatment, the scores of abdominal pain, loose stool, mental fatigue, stool frequency and anorexia, and IBS-BSS score of the two groups decreased after treatment, IBS-QOL score increased (P<0.05). After treatment, the scores of abdominal pain, loose stool, mental fatigue, stool frequency and anorexia in the observation group were lower than those in the control group ( P<0.05), the IBS-BSS score was lower than that in the control group (P<0.01), the IBS-QOL score was higher than that of the control group (P<0.01). Compared with before treatment, the levels of 5-HT, VIP, SP, DAO, D-lactic acid and ET in the two groups decreased (P<0.05). After treatment, the levels of 5-HT, VIP, SP, DAO, D-lactic acid and ET in the observation group were lower than those in the control group (P<0.01). There were no adverse reactions in the two groups. Conclusion Qilian Jiechangning Decoction for IBS-D patients with spleen deficiency and dampness heat syndrome can improve TCM symptom scores, promote quality of life, regulate brain gut peptide, and improve intestinal mucosal barrier function, which has good clinical efficacy and safety.
参考文献/References:
[1] MEARIN F, LACY B E, CHANG L, et al. Bowel disorders[J]. Gastroenterology,2016,150：1393-1407. [2] FORD A C, LACY B E, TALLEY N J. Irritable bowel syndrome[J]. N Engl J Med,2017,376(26)：2566-2578. [3] 万凌峰.中医药治疗腹泻型肠易激综合征的临床研究进展[J].中国中医急症,2020,29(1)：171-173. [4] 蒋士生,李勇敏,朱克俭,等.芪连结肠宁片对大鼠慢性非特异性溃疡性结肠炎的影响[J].中国实验方剂学杂志,2011,17(23)：217-219. [5] 中华中医药学会脾胃病分会.肠易激综合征中医诊疗专家共识意见(2017)[J].中医杂志,2017,58(18)：1614-1620. [6] 中国中西医结合学会消化系统疾病专业委员会.胃肠疾病中医症状评分表[J].中国中西医结合消化杂志,2011,19(1)：66-68. [7] FRANCIS C Y, MORRIS J, WHORWELL P J. The irritable bowel severity scoring system：A simple method of monitoring irritable bowel syndrome and its progress[J]. Aliment Pharmacol Ther,1997,11(2)：395-402. [8] HAHN B A, KIRCHDOERFER L J, FULLERTON S, et al. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome[J]. Aliment Pharmacol Ther,1997,11(3)：547-552. [9] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京：中国医药科技出版社,2002：139-142. [10] 张霞,蒋欢欢,赵汉清,等.双歧杆菌四联活菌胶囊治疗肠易激综合征的临床效果[J].中国医药导报,2016,13(15)：154-157. [11] 王思玉,彭美哲,李享,等.健脾安肠汤联合匹维溴胺治疗肠易激综合征的临床疗效及对血清5-HT、CGRP、SP、VIP水平的影响[J].现代生物医学进展,2019,19(13)：2476-2480. [12] 陈军亮,樊志敏.肠屏障功能常用血清学检测现状及进展[J].结直肠肛门外科,2009,15(3)：207-209.
相似文献/References:
[1]汪红兵,张声生,李振华,等.360例腹泻型肠易激综合征主要证候分布与不同因素关系的研究[J].中国中医药信息杂志,2010,17(3):18.
WANG Hong-bing,ZHANG Sheng-sheng,LI Zhen-hua,et al.Study on Relationship between the Main Symptoms Distribution and Different Factors of 360 Cases of IBS-D[J].zhongguo zhongyiyao xinxi zazhi,2010,17(2):18.
[2]赵钟文,吴宽裕,乐宇民,等.扶脾养胃法治疗急性类风湿关节炎临床研究[J].中国中医药信息杂志,2008,15(7):61.
[J].zhongguo zhongyiyao xinxi zazhi,2008,15(2):61.
[3]吴玉泓.柴胡桂枝汤加味治疗腹泻型肠易激综合征体会[J].中国中医药信息杂志,2008,15(12):86.
[J].zhongguo zhongyiyao xinxi zazhi,2008,15(2):86.
[4]何高潮,李刚毅,李宏军,等.肠易康治疗腹泻型肠易激综合征临床观察[J].中国中医药信息杂志,2007,14(9):70.
[J].zhongguo zhongyiyao xinxi zazhi,2007,14(2):70.
[5]常东,李健,冯春霞,等.易激灵2号方对腹泻型肠易激综合征患者近期生活质量的影响[J].中国中医药信息杂志,2012,19(2):7.[doi:10.3969/j.issn.1005-5304.2012.02.004]
CHANG Dong,LI Jian,FENG Chun-xia,et al.Effect of Yijiling-2 on Short-term Quality of Life in Patients with Diarrhea Type Irritable Bowel Syndrome[J].zhongguo zhongyiyao xinxi zazhi,2012,19(2):7.[doi:10.3969/j.issn.1005-5304.2012.02.004]
[6]张雪梅.中西医结合治疗腹泻型肠易激综合征临床观察[J].中国中医药信息杂志,2006,13(10):74.
[J].zhongguo zhongyiyao xinxi zazhi,2006,13(2):74.
[7]罗琦,廉永红,苏俊权,等.加味四君子汤对脾虚型肠易激综合征患者肠黏膜5-羟色胺受体的影响[J].中国中医药信息杂志,2013,20(1):19.[doi:10.3969/j.issn.1005-5304.2013.01.008]
LUO Qi,LIAN Yong-hong,SU Jun-quan,et al.Effect of Modified Sijunzi Decoction on 5-HT Receptors in Intestinal Mucosa of IBS-D Patients with Spleen-Deficiency Syndrome[J].zhongguo zhongyiyao xinxi zazhi,2013,20(2):19.[doi:10.3969/j.issn.1005-5304.2013.01.008]
[8]吴永红,郑国荣.四磨汤口服液联合复方谷氨酰胺肠溶胶囊治疗腹泻型肠易激综合征临床研究[J].中国中医药信息杂志,2013,20(8):11.[doi:10.3969/j.issn.1005-5304.2013.08.005]
[J].zhongguo zhongyiyao xinxi zazhi,2013,20(2):11.[doi:10.3969/j.issn.1005-5304.2013.08.005]
[9]周军丽,张 颖.中医辨证治疗腹泻型肠易激综合征[J].中国中医药信息杂志,2005,12(5):57.
[10]武建华.温针灸治疗腹泻型肠易激综合征疗效观察[J].中国中医药信息杂志,2014,21(11):98.[doi:10.3969/j.issn.1005-5304.2014.11.030]
备注/Memo
基金项目：全国名老中医药专家传承工作室建设项目（2013年）；湖南中医药大学国内一流学科建设资助项目（2018－2020年）
更新日期/Last Update:
2021-01-26